Sharp Edge Labs Inc. announced that it has entered into a drug discovery collaboration agreement with Sumitomo Dainippon Pharma CO., Ltd. As part of the collaboration, Sumitomo Dainippon Pharma will make its proprietary compound library available to Sharp Edge Labs for use in their drug discovery platform with a goal of identifying lead compounds and potential development candidates for neurodegenerative disorders.  Sumitomo Dainippon Pharma's library has been specifically chosen to maximize blood-brain barrier penetration, increasing the chances that any small molecule lead discovered in collaboration will have access to the CNS.  Sharp Edge Labs' proprietary biosensor platform will be used to screen for and identify compounds that can correct a trafficking defect known to be involved in several neurodegenerative diseases.  Sharp Edge Labs will use their technology to further characterize the cellular mechanism of potential lead compounds including assessing their activity in cells from patients.